ClinicalTrials.gg
CompletedNCT02006706Updated Aug 21, 2017Results posted

A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy

A Phase 3 interventional study of rituximab [MabThera/Rituxan] and methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 3 sites in Serbia. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-08-21.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 7 years 3 months after the study started (first participant enrolled Aug 2006, registered Dec 2013).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.

Enrollment
57th of 63
15 · median 159
Started
2006
with 10 others
Phase 3
27 of 63
1 open now
Registered
44th of 63
by date
Lead sponsor
20 of 63
Hoffmann-La Roche

Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 57th largest by enrollment, is one of 11 that started in 2006, is one of 27 in phase 3, and was the 44th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing rituximab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of MabThera/Rituxan plus methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to at least 1 DMARD treatment. All patients will receive MabThera (1000mg iv infusion) on days 1 and 15, and methotrexate (10-25mg po) weekly. The anticipated time on study treatment is 3-12 months.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, 18-80 years of age;
  • rheumatoid arthritis after inadequate response to >=1 DMARD treatment;
  • active disease;
  • DMARDs other than methotrexate withdrawn for at least 4 weeks prior to start of study treatment.

Exclusion criteria

Exclusion Criteria:

  • disease other than rheumatoid arthritis;
  • bone/joint surgery within 8 weeks prior to screening, or joint surgery planned within 24 weeks of MabThera infusion;
  • concurrent treatment with any DMARD or antiTNF-alfa;
  • intra-articular or parenteral within 4 weeks prior to screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    MabThera/Rituxan

    Drug: rituximab [MabThera/Rituxan] · Drug: methotrexate · Drug: methylprednisolone

Interventions

  • Drugrituximab [MabThera/Rituxan]

    Drug page: Rituximab

    1000 mg iv Days 1 and 15

  • 10 - 25 mg/week

  • iv administration on Day 1 and 15 prior to MabThera/Rituxan infusion

06

What researchers measure

Primary outcomes

  1. Change From Baseline Disease Activity Score Based on 28-Joint Count (DAS28) at Week 24

    DAS28 was calculated from the number of swollen joints and painful joints using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour \[mm/hour\]) and patient's global assessment (PGA) of disease activity (participant-rated arthritis activity assessment using visual analog scale \[VAS\]) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 less than or equal to (≤)3.2 equals (=) low disease activity, DAS28 greater than (\>)3.2 to 5.1 = moderate to high disease activity.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Health Assessment Questionnaire-Disability Index (HAQ-DI)

    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

    Time frame: Baseline, Week 24

07

Results

Posted Nov 6, 2014

Participant flow

Participant flow — Overall Study
MilestoneRituximab/Methylprednisolone/Methotrexate (MTX)
Started15
Completed14
Not completed1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryChange From Baseline Disease Activity Score Based on 28-Joint Count (DAS28) at Week 24

DAS28 was calculated from the number of swollen joints and painful joints using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour \[mm/hour\]) and patient's global assessment (PGA) of disease activity (participant-rated arthritis activity assessment using visual analog scale \[VAS\]) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 less than or equal to (≤)3.2 equals (=) low disease activity, DAS28 greater than (\>)3.2 to 5.1 = moderate to high disease activity.

Time frame:
Baseline, Week 24
Reported as:
Mean · score on a scale
Change From Baseline Disease Activity Score Based on 28-Joint Count (DAS28) at Week 24
score on a scaleRituximab/Methylprednisolone/MTX
Change From Baseline Disease Activity Score Based on 28-Joint Count (DAS28) at Week 242.98 ± 1.80
Statistical analysis
  • Rituximab/Methylprednisolone/MTX · t-test, 2 sided · p = <0.001 · Mean difference (final values): 2.98 · 95% CI 1.73 to 4.22The null hypothesis was that there was no difference between the DAS28 at baseline and DAS28 after 24 weeks of follow-up
SecondaryHealth Assessment Questionnaire-Disability Index (HAQ-DI)

HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

Time frame:
Baseline, Week 24
Reported as:
Mean · score on a scale
Health Assessment Questionnaire-Disability Index (HAQ-DI)
score on a scaleRituximab/Methylprednisolone/MTX
Baseline1.91 ± 0.687
Week 241.05 ± 0.960
Statistical analysis
  • Rituximab/Methylprednisolone/MTX · t-test, 2 sided · p = <0.001

Adverse events

Collected over Adverse events (AEs) were reported starting with the first dose of study drug through the end of the study (24 weeks total).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab/Methylprednisolone/MTX—2/14 (14.3%)0/14 (0%)
Most frequent serious events
Most frequent serious events
EventRituximab/Methylprednisolone/MTX
Infarctus myocardiiCardiac disorders1/14
Enterocolitis acutaGastrointestinal disorders1/14

Baseline characteristics

Per-protocol (PP) population: The 14 enrolled participants who were compliant with the protocol and not lost to follow-up.

Age, Continuous
Age, Continuous(years)Rituximab/Methylprednisolone/MTX
Mean52.29 ± 11.89
Age, Categorical
Age, Categorical(Participants)Rituximab/Methylprednisolone/MTX
<=18 years0
Between 18 and 65 years13
>=65 years1
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab/Methylprednisolone/MTX
Female9
Male5
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rituximab/Methylprednisolone/MTX
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White14
More than one race0
Unknown or Not Reported0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rituximab/Methylprednisolone/MTX
Hispanic or Latino0
Not Hispanic or Latino14
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Rituximab/Methylprednisolone/MTX
Serbia14
08

Study locations

3 sites
  • Belgrade, 11000, Serbia
  • Niska Banja, 18250, Serbia
  • Nova Sad, 21000, Serbia
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2006 to primary completion in Nov 2007, 15 months.

Results were first posted in Nov 2014, 6 years 11 months after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 15 months is below that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2013
First posted
Dec 10, 2013
StartActual
Aug 10, 2006
Primary completionActual
Nov 23, 2007
CompletionActual
Nov 23, 2007
Results first posted
Nov 6, 2014
Last update
Aug 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02006706
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 10, 2013
Start date
Aug 10, 2006
Primary completion
Nov 23, 2007
Completion
Nov 23, 2007
Results posted
Nov 6, 2014
Last update
Aug 21, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rituximab · Methotrexate

Start the discussion